Patents by Inventor Craig R. Gibeau

Craig R. Gibeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRMT5 INHIBITORS
    Publication number: 20230114091
    Abstract: The present invention provides a compound of Formula (I) (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 13, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michelle Machacek, Michael D. Altman, Shuhei Kawamura, Michael H. Reutershan, David L. Sloman, Phieng Siliphaivanh, Sebastian E. Schneider, Charles S. Yeung, David J. Witter, Craig R. Gibeau
  • PRMT5 INHIBITORS
    Publication number: 20230108114
    Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 6, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michelle Machacek, Michael D. Altman, Chunghui Huang, Michael H. Reutershan, David L. Sloman, Phieng Siliphaivanh, Sebastian E. Schneider, Charles S. Yeung, David J. Witter, Craig R. Gibeau, Yingchun Ye
  • PRMT5 INHIBITORS
    Publication number: 20230108452
    Abstract: The present invention provides a compound selected from: compounds A, B, C, D and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 6, 2023
    Inventors: Michelle Machacek, Michael D. Altman, Chunhui Huang, Michael H. Reutershan, David L. Sloman, David J. Witter, Craig R. Gibeau
  • PRMT5 INHIBITORS
    Publication number: 20230092404
    Abstract: The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
    Type: Application
    Filed: December 14, 2020
    Publication date: March 23, 2023
    Inventors: Michelle Machacek, Michael D. Altman, Shuhei Kawamura, David L. Sloman, David J. Witter, Craig R. Gibeau
  • Tricyclic compounds as inhibitors of mutant IDH enzymes
    Patent number: 10508108
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R1)? or —N?; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, J. Michael Ellis, Sara Esposite, Dawn M. Hoffman, Chunhui Huang, Solomon D. Kattar, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Dann L. Parker, Jr., Michael H. Reutershan, Nunzio Sciammetta, Pengcheng P. Shao, David L. Sloman, Wanying Sun, Feroze Ujjainwalla, Zhicai Wu, Yang Yu, Craig R. Gibeau
  • Pyrrolotriazine inhibitors of IRAK4 activity
    Patent number: 10329295
    Abstract: The present invention relates to pyrrolotriazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: June 25, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Michael D. Altman, Jason D. Brubaker, Craig R. Gibeau
  • Pyrazolopyrimidine inhibitors of IRAK4 activity
    Patent number: 10329294
    Abstract: The present invention relates to pyrazolopyrimidine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: June 25, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Michael D. Altman, Jason D. Brubaker, Craig R. Gibeau
  • Carboxamide inhibitors of IRAK4 activity
    Patent number: 10155765
    Abstract: The present invention relates to carboxamide inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: December 18, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Michael D. Altman, Matthew L. Childers, Craig R. Gibeau, Ginny Dai Ho, Honchung Tsui
  • Thienopyrazine inhibitors of IRAK4 activity
    Patent number: 10040802
    Abstract: The present invention relates to thienopyrazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: August 7, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Michael D. Altman, Craig R. Gibeau
  • Pyrrolopyridazine inhibitors of IRAK4 activity
    Patent number: 10040798
    Abstract: The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: August 7, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Michael D. Altman, Jason D. Brubaker, Craig R. Gibeau
  • Inhibitors of IRAK4 activity
    Patent number: 9969749
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian M. Andresen, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. MacLean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Luis Torres
  • Inhibitors of IRAK4 activity
    Patent number: 9943516
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 17, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brian M. Andresen, Jason D. Brubaker, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Charles A. Lesburg, Jongwon Lim, John K. F. Maclean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith, Luis Torres
  • Inhibitors of IRAK4 activity
    Patent number: 9932350
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: April 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. Maclean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith
  • Inhibitors of IRAK4 activity
    Patent number: 9926330
    Abstract: The present invention relates to inhibitors of IRAK4 of Formula I and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: March 27, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Michael D. Altman, Jason D. Brubaker, Matthew L. Childers, Anthony Donofrio, Thierry Fischmann, Craig R. Gibeau, Solomon D. Kattar, Charles A. Lesburg, Jongwon Lim, John K. F. MacLean, Umar F. Mansoor, Alan B. Northrup, John M. Sanders, Graham F. Smith
  • THIENOPYRAZINE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051035
    Abstract: The present invention relates to thienopyrazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, CRAIG R. GIBEAU
  • PYRROLOTRIAZINE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051030
    Abstract: The present invention relates to pyrrolotriazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, JASON D. BRUBAKER, CRAIG R. GIBEAU
  • CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051027
    Abstract: The present invention relates to carboxamide inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, MATTHEW L. CHILDERS, CRAIG R. GIBEAU, GINNY DAI HO, HONCHUNG TSUI
  • PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051028
    Abstract: The present invention relates to pyrazolopyrimidine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, JASON D. BRUBAKER, CRAIG R. GIBEAU
  • PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY
    Publication number: 20180051029
    Abstract: The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 22, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JONGWON LIM, MICHAEL D. ALTMAN, JASON D. BRUBAKER, CRAIG R. GIBEAU
  • NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
    Publication number: 20170369507
    Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Application
    Filed: December 1, 2015
    Publication date: December 28, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Fischer Christian, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, Michael J. Ellis, Sara Esposite, Qingmei Hong, Chunhui Huang, Alexander J. Kim, John W. Lampe, Michelle R. Machacek, Daniel R. McMasters, Ryan D. Otte, Dann L. Parker, Jr., Michael H. Reutershan, Nunzio Sciammetta, Patrick Pengcheng Shao, David L. Sloman, Feroze Ujjainwalla, Catherine White, Zhicai Wu, Yang Yu, Kake Zhao, Craig R. Gibeau